Targeting tumor‐infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma

CJ Chang, YH Yang, CJ Chiu, LC Lu… - … journal of cancer, 2018 - Wiley Online Library
Sorafenib, a multikinase inhibitor with antiangiogenic activity, is an approved therapy for
hepatocellular carcinoma (HCC). It is unclear whether the proinflammatory and …
被引用次数：54 相关文章

Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma

CJ Chang, YH Yang, CJ Chiu, LC Lu… - … journal of cancer, 2018 - pubmed.ncbi.nlm.nih.gov
Sorafenib, a multikinase inhibitor with antiangiogenic activity, is an approved therapy for
hepatocellular carcinoma (HCC). It is unclear whether the proinflammatory and …
[PDF] researchgate.net

[PDF][PDF] Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma

CJ Chang, YH Yang, CJ Chiu, LC Lu, CC Liao… - researchgate.net
Hepatocellular carcinoma (HCC) is an important malignant disease worldwide, especially in
East Asian and African countries. 1 Sorafenib, a multikinase inhibitor with antiangiogenic …

[引用][C] Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma

CJ Chang, YH Yang, CJ Chiu, LC Lu, CC Liao… - International Journal of …, 2017 - cir.nii.ac.jp
Targeting tumor-infiltrating Ly6G<sup>+</sup> myeloid cells improves sorafenib efficacy in
mouse orthotopic hepatocellular carcinoma | CiNii Research CiNii 国立情報学研究所 学術情報 …

Targeting tumor-infiltrating Ly6G+ myeloid cells improves sorafenib efficacy in mouse orthotopic hepatocellular carcinoma.

CJ Chang, YH Yang, CJ Chiu, LC Lu… - … Journal of Cancer, 2017 - europepmc.org
Sorafenib, a multikinase inhibitor with antiangiogenic activity, is an approved therapy for
hepatocellular carcinoma (HCC). It is unclear whether the proinflammatory and …